0001104659-23-071602.txt : 20230615 0001104659-23-071602.hdr.sgml : 20230615 20230615161018 ACCESSION NUMBER: 0001104659-23-071602 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230612 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230615 DATE AS OF CHANGE: 20230615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MedTech Acquisition Corp CENTRAL INDEX KEY: 0001826667 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 853009869 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39813 FILM NUMBER: 231017432 BUSINESS ADDRESS: STREET 1: 48 MAPLE AVENUE CITY: GREENWICH STATE: CT ZIP: 06830 BUSINESS PHONE: 6462096063 MAIL ADDRESS: STREET 1: 48 MAPLE AVENUE CITY: GREENWICH STATE: CT ZIP: 06830 8-K 1 tm2318652d1_8k.htm FORM 8-K
0001826667 false --12-31 0001826667 2023-06-12 2023-06-12 0001826667 MTAC:UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember 2023-06-12 2023-06-12 0001826667 us-gaap:CommonClassAMember 2023-06-12 2023-06-12 0001826667 us-gaap:WarrantMember 2023-06-12 2023-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 12, 2023

 

MedTech Acquisition Corporation

(Exact name of registrant as specified in its charter)

 

Delaware   001-39813   85-3009869
(State or other jurisdiction of
incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

48 Maple Avenue,
Greenwich, CT		   06830
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 391-1288

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange on
which registered
Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant   MTACU   The Nasdaq Stock Market LLC
Class A common stock, par value $0.0001 per share   MTAC   The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share   MTACW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ 

 

 

 

 

  

Item 1.01. Entry into a Material Definitive Agreement.

  

On June 15, 2023, MedTech Acquisition Corporation, a Delaware corporation (“MedTech” or the “Company”), issued a promissory note (the “Extension Note”) in the aggregate principal amount of up to $137,375.28 to the Company’s sponsor, MedTech Acquisition Sponsor LLC (the “Sponsor”) pursuant to which the Sponsor agreed to loan to the Company up to $137,375.28 to deposit into the Company’s trust account (the “Trust Account”) for the shares of Class A common stock of the Company (the “Public Shares”) that were not redeemed in connection with the extension of the Company’s termination date from June 22, 2023 to September 22, 2023 or such earlier date as determined by the board of directors of the Company (the “Board”). The Extension Note bears no interest and is repayable in full upon the date of the consummation of an initial business combination (the “Business Combination”).

 

The Company will deposit $0.04 per share into the Trust Account for each month (commencing on June 23, 2023 and ending on the 22nd day of each subsequent month), or portion thereof, that is needed by the Company to complete a Business Combination until September 22, 2023 or such earlier date as determined by the Board (the “Extension”).

  

The issuance of the Extension Note was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.

 

The foregoing description of the Extension Note does not purport to be complete and is qualified in its entirety by reference to the full text of the Extension Note, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1, and is incorporated herein by reference.

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-balance Sheet Arrangement of a Registrant.

 

The disclosure contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 2.03. 

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On June 12, 2023, the Company held a special meeting of stockholders (the “Meeting”). At the Meeting, the Company’s stockholders approved (1) an amendment to the Company’s Amended and Restated Certificate of Incorporation, including the amendment thereto (the “Charter”), to extend the date by which the Company must consummate its Business Combination from June 22, 2023 to September 22, 2023 (or such earlier date as determined by the Board); (2) an amendment to the Charter such that subject to the rights of the holders of any outstanding class of preferred stock, the number of authorized shares of any class of common stock or preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the outstanding shares of the Company’s capital stock entitled to vote thereon, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law; (3) an amendment to the Charter to provide for the right of the holder of the Company’s Class B common stock, par value $0.0001 per share (the “Founder Shares”), to convert into Class A common stock, par value $0.0001 per share, on a one-for-one basis at any time prior to the closing of a Business Combination at the option of the holder of Founder Shares; and (4) amendments to the Charter to eliminate from the Charter the limitation that the Company may not redeem public shares to the extent that such redemption would result in the Company having net tangible assets of less than $5,000,001 (all the aforementioned amendments, collectively, the “Charter Amendments”). The Company filed the Charter Amendments with the Secretary of State of the State of Delaware on June 12, 2023.

 

The foregoing description of the Charter Amendments does not purport to be complete and is qualified in its entirety by reference to the Charter Amendments, a copy of which is attached as Exhibit 3.1 hereto and is incorporated by reference herein.

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

At the Meeting, an aggregate of 7,497,322 shares of the Company’s common stock, which represents a quorum of the outstanding shares of common stock entitled to vote as of the record date of April 28, 2023, were represented in person or by proxy at the Meeting.

 

At the Meeting, the Company’s stockholders voted on the following proposals, each of which was approved:

 

(1) The Extension Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate a Business Combination from June 22, 2023 to September 22, 2023 (or such earlier date as determined by the Board). The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders:

 

FOR   AGAINST   ABSTAIN
6,333,932   1,163,390   0

 

(2) Section 242(b)(2) Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation such that subject to the rights of the holders of any outstanding class of preferred stock, the number of authorized shares of any class of common stock or preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the outstanding shares of the Company’s capital stock entitled to vote thereon, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law. The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders:

 

    FOR   AGAINST   ABSTAIN
common stock   7,496,754   568   0
Class A common stock   1,246,754   568   0
Class B common stock   6,250,000   0   0

 

(3) Founder Share Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to provide for the right of the holder of the Founder Shares to convert into Class A common stock, par value $0.0001 per share, on a one-for-one basis at any time prior to the closing of a Business Combination at the option of the holder of the Founder Shares. The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders:

 

FOR   AGAINST   ABSTAIN
7,496,750   572   0

 

(4) Redemption Limitation Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to eliminate the limitation that the Company may not redeem public shares to the extent that such redemption would result in the Company having net tangible assets of less than $5,000,001 in order to allow the Company to redeem public shares irrespective of whether such redemption would exceed the redemption limitation. The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders:

 

FOR   AGAINST   ABSTAIN
7,496,690   322   310

 

In connection with the Meeting, stockholders holding 808,628 Public Shares exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $8.48 million (approximately $10.49 per Public Share) will be removed from the Trust Account to pay such holders and approximately $12.00 million will remain in the Trust Account. Following redemptions, the Company has 1,144,794 public shares outstanding, and the Company will deposit $45,791.76 into the Trust Account of which 50% will be drawn down under the Extension Note and 50% will be funded by TriSalus Life Sciences, Inc., a Delaware corporation, pursuant to the Agreement and Plan of Merger entered into on November 11, 2022.

 

 

 

  

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits. The following exhibits are filed with this Form 8-K:

 

Exhibit No.   Description of Exhibits
3.1   Second Amendment to Amended and Restated Certificate of Incorporation.
10.1   Promissory Note issued to MedTech Acquisition Sponsor LLC, dated June 15, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

  

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MEDTECH ACQUISITION CORP.
   
Dated: June 15, 2023 By: /s/ Christopher C. Dewey
  Name: Christopher C. Dewey
  Title: Chief Executive Officer

 

 

 

 EX-3.1 2 tm2318652d1_ex3-1.htm EXHIBIT 3.1

Exhibit 3.1

 

SECOND AMENDMENT
TO THE
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
MEDTECH ACQUISITION CORPORATION

 

Pursuant to Section 242 of the
Delaware General Corporation Law

 

MedTech Acquisition Corporation (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, does hereby certify as follows:

 

1. The name of the Corporation is MedTech Acquisition Corporation. The Corporation’s Certificate of Incorporation was filed in the office of the Secretary of State of the State of Delaware on September 11, 2020 (the “Original Certificate”). An Amended and Restated Certificate of Incorporation was filed in the office of the Secretary of State of the State of Delaware on December 17, 2020 and was subsequently amended by the filing of the Amendment to the Amended and Restated Certificate of Incorporation filed on December 12, 2022 (as amended, the “Amended and Restated Certificate of Incorporation”).

 

2. This Second Amendment to the Amended and Restated Certificate of Incorporation amends the Amended and Restated Certificate of Incorporation of the Corporation.

 

3. This Second Amendment to the Amended and Restated Certificate of Incorporation was (i) duly adopted by the affirmative vote of the holders of 65% of the stock entitled to vote at a meeting of stockholders in regards to amendments to Sections 4.3(b)(i), 9.1(b), 9.2(a), 9.2(e), 9.2(f), 9.4, and 9.7, and (ii) duly adopted by the affirmative vote of (x) a majority of the holders of the outstanding common stock voting together as a single class, (y) a majority of the outstanding Class B common stock voting as a separate class and (z) a majority of the holders of the outstanding Class A common stock voting as a separate class, in regards to the amendment to Section 4.1, at a meeting of stockholders in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware (the “DGCL”).

 

4. The text of Section 4.1 of Article IV is hereby amended and restated to read in full as follows:

 

4.1 Authorized Capital Stock. The total number of shares of all classes of capital stock, each with a par value of $0.0001 per share, which the Corporation is authorized to issue is 111,000,000 shares, consisting of (a) 110,000,000 shares of common stock (the “Common Stock”), including (i) 100,000,000 shares of Class A Common Stock (the “Class A Common Stock”), and (ii) 10,000,000 shares of Class B Common Stock (the “Class B Common Stock”), and (b) 1,000,000 shares of preferred stock (the “Preferred Stock”). The number of authorized shares of Class A Common Stock or Preferred Stock, or any series thereof, may be increased or decreased (but not below the number of shares thereof then outstanding plus, if applicable, the number of shares of Class A Common Stock or Preferred Stock or such series, as applicable, reserved for issuance) by the affirmative vote of the holders of a majority of the voting power of all of the outstanding shares of stock of the Corporation entitled to vote thereon, irrespective of the provisions of Section 242(b)(2) of the DGCL (or any successor provision thereto) and without a separate vote of the holders of the Class A Common Stock or the Preferred Stock, or of any series thereof, unless a vote of any such holders is required pursuant to this Amended and Restated Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock). The holders of Class B Common Stock are entitled to vote as a separate class to increase the authorized number of shares of Class B Common Stock. 

  

5. The text of Section 4.3(b)(i) of Article IV is hereby amended and restated to read in full as follows:

 

Shares of Class B Common Stock shall be convertible into shares of Class A Common Stock on a one-for-one basis (the “Initial Conversion Ratio”) automatically upon the closing of the Business Combination or at any time prior to the closing of the Business Combination at the option of the holder of such shares of Class B Common Stock.

 

 

 

 

6. The text of Section 9.1(b) of Article IX is hereby amended and restated to read in full as follows:

 

(b) Immediately after the Offering, a certain amount of the net offering proceeds received by the Corporation in the Offering (including the proceeds of any exercise of the underwriters’ over-allotment option) and certain other amounts specified in the Corporation’s registration statement on Form S-1, as initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 30, 2020, as amended (the “Registration Statement”), shall be deposited in a trust account (the “Trust Account”), established for the benefit of the Public Stockholders (as defined below) pursuant to a trust agreement described in the Registration Statement. Except for the withdrawal of interest to pay taxes (less up to $100,000 of interest to pay dissolution expenses), none of the funds held in the Trust Account (including the interest earned on the funds held in the Trust Account) will be released from the Trust Account until the earliest to occur of (i) the completion of the initial Business Combination, (ii) the redemption of 100% of the Offering Shares (as defined below) if the Corporation is unable to complete its initial Business Combination by September 22, 2023 (or, if the Office of the Delaware Division of Corporations shall not be open for a full business day (including filing of corporate documents) on such date the next date upon which the Office of the Delaware Division of Corporations shall be open for a full business day (the “Deadline Date”) and (iii) the redemption of shares in connection with a vote seeking to amend such provisions of this Amended and Restated Certificate (a) to modify the substance or timing of the Corporation’s obligation to provide for the redemption of the Offering Shares in connection with an initial Business Combination or to redeem 100% of such shares if the Corporation has not consummated an initial Business Combination by the Deadline Date or (b) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity (as described in Section 9.7). Holders of shares of Common Stock included as part of the units sold in the Offering (the “Offering Shares”) (whether such Offering Shares were purchased in the Offering or in the secondary market following the Offering and whether or not such holders are either MedTech Acquisition Sponsor LLC (the “Sponsor”) or officers or directors of the Corporation, or affiliates of any of the foregoing) are referred to herein as “Public Stockholders.”

 

7. The text of Section 9.2(a) of Article IX is hereby amended and restated to read in full as follows:

 

(a) Prior to the consummation of the initial Business Combination, the Corporation shall provide all holders of Offering Shares with the opportunity to have their Offering Shares redeemed upon the consummation of the initial Business Combination (irrespective of whether they voted in favor or against the Business Combination) pursuant to, and subject to the limitations of, Sections 9.2(b) and 9.2(c) hereof (such rights of such holders to have their Offering Shares redeemed pursuant to such Sections, the “Redemption Rights”) for cash equal to the applicable redemption price per share determined in accordance with Section 9.2(b) hereof (the “Redemption Price”). Notwithstanding anything to the contrary contained in this Amended and Restated Certificate, there shall be no Redemption Rights or liquidating distributions with respect to any warrant issued pursuant to the Offering.

 

8. The text of Section 9.2(e) of Article IX is hereby amended and restated to read in full as follows:

 

If the Corporation offers to redeem the Offering Shares in conjunction with a stockholder vote on an initial Business Combination, the Corporation shall consummate the proposed initial Business Combination only if such initial Business Combination is approved by the affirmative vote of the holders of a majority of the shares of the Common Stock that are voted at a stockholder meeting held to consider such initial Business Combination. 

 

 

 

  

 

9. The following text of Section 9.2 (f) of Article IX is hereby deleted in its entirety:

 

If the Corporation conducts a tender offer pursuant to Section 9.2(b), the Corporation shall consummate the proposed initial Business Combination only if the Redemption Limitation is not exceeded. 

 

10. The text of Section 9.4 of Article IX is hereby amended and restated to read in full as follows:

 

Share Issuances. Prior to the consummation of the Corporation’s initial Business Combination, the Corporation shall not issue any additional shares of capital stock of the Corporation that would entitle the holders thereof to receive funds from the Trust Account or vote on any initial Business Combination, on any pre-Business Combination activity or on any amendment to this Article IX, provided that the issuance of any shares of Class A common stock upon conversion of shares of Class B common stock shall not be subject to the foregoing limitation.

 

11. The text of Section 9.7 of Article IX is hereby amended and restated to read in full as follows:

 

Additional Redemption Rights. If, in accordance with Section 9.1(a), any amendment is made to Section 9.2(d) (i) to modify the substance or timing of the Corporation’s obligation to provide for the redemption of the Offering Shares in connection with an initial Business Combination or to redeem 100% of such shares if the Corporation has not consummated an initial Business Combination by the Deadline Date or (ii) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity, the Public Stockholders shall be provided with the opportunity to redeem their Offering Shares upon the approval of any such amendment, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Corporation to pay its taxes, divided by the number of then outstanding Offering Shares.

 

IN WITNESS WHEREOF, MedTech Acquisition Corporation has caused this Amendment to the Amended and Restated Certificate to be duly executed in its name and on its behalf by an authorized officer as of this 12th day of June, 2023.

 

  MEDTECH ACQUISITION CORPORATION
   
  By: /s/ Christopher C. Dewey
  Name: Christopher C. Dewey
  Title: Chief Executive Officer

 

 

 

 

 

 

 EX-10.1 3 tm2318652d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

PROMISSORY NOTE

 

  Dated as of June 15, 2023
Principal Amount: Up to $137,375.28 New York, New York
   

 

MedTech Acquisition Corporation, a special purpose acquisition company incorporated as a Delaware corporation (the “Maker”), promises to pay to the order of MedTech Acquisition Sponsor LLC, or its registered assigns or successors in interest (the “Payee”), or order, the principal sum of up to $137,375.28 in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

 

1.       Principal. The principal balance of this Note shall be due and payable by the Maker (such date, the “Maturity Date”), subject to Section 12 below, (a) upon the consummation of the Maker’s proposed initial business combination and (b) the date of the liquidation of the Maker.

 

2.       Interest. No interest shall accrue on the unpaid principal balance of this Note.

 

3.       Drawdown Requests. The Payee will fund up to $137,375.28 into the trust account of the Maker established in connection with its initial public offering and currently maintained by Continental Stock Transfer & Trust Company, a New York corporation (the “Trust Account”), such amounts to be for the benefit of the holders of the Maker’s unredeemed shares of Class A common stock upon redemption or liquidation of the Maker in accordance with the Maker’s amended and restated certificate of incorporation, as amended. The principal of this Note may be drawn down in three equal amounts of $45,791.76 per withdraw, between the 22nd and 29th of each month (or portion thereof) from June 2023 through September 2023 (provided that the first withdrawal hereunder may be made concurrently with the execution hereof), up until the date on which the Maker consummates its initial business combination, upon written request from the Maker to the Payee (each, a “Drawdown Request”). Each Drawdown Request must be made before the 7th of each applicable monthly period (provided that, with respect to the first Drawdown Request hereunder, such Drawdown Request may be made concurrently with the execution hereof), and state the amount to be drawn down. The Payee, in its sole discretion, shall fund each Drawdown Request via a wire transfer directly to the Trust Account no later than the 29th of each appliable monthly period; provided, however, that the maximum amount of drawdowns collectively under this Note shall not exceed $137,375.28. Once an amount is drawn down under this Note, it shall not be available for future Drawdown Requests. Except as set forth herein, no fees, payments or other amounts shall be due to the Payee in connection with, or as a result of, any Drawdown Request by the Maker.

 

4.       Application of Payments. All payments shall be applied first to payment in full of any costs incurred in the collection of any sum due under this Note, including, without limitation, reasonable attorneys’ fees, and then to the payment in full of any late charges and finally to the reduction of the unpaid principal balance of this Note.

 

5.       Events of Default. The following shall constitute an event of default (“Event of Default”):

 

(a)       Failure to Make Required Payments. Failure by the Maker to pay the principal amount due pursuant to this Note within five (5) business days of the Maturity Date.

 

(b)       Voluntary Bankruptcy, Etc. The commencement by the Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of the Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of the Maker generally to pay its debts as such debts become due, or the taking of corporate action by the Maker in furtherance of any of the foregoing.

 

 

 

 

(c)       Involuntary Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of the Maker in an involuntary case under any applicable bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of the Maker or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of sixty (60) consecutive days.

 

6.       Remedies.

 

(a)       Upon the occurrence of an Event of Default specified in Section 5(a) hereof, the Payee may, by written notice to the Maker, declare this Note to be due immediately and payable, whereupon the unpaid principal amount of this Note, and all other amounts payable hereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding.

 

(b)       Upon the occurrence of an Event of Default specified in Sections 5(b) and 5(c), the unpaid principal balance of this Note, and all other sums payable with regard to this Note, shall automatically and immediately become due and payable, in all cases without any action on the part of the Payee.

 

7.       Waivers. The Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard to this Note, all errors, defects and imperfections in any proceedings instituted by the Payee under the terms of this Note, and all benefits that might accrue to the Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment, and the Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof or any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by the Payee.

 

8.       Unconditional Liability. The Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by the Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by the Payee with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to the Maker or affecting the Maker’s liability hereunder.

 

9.       Notices. All notices, statements or other documents which are required or contemplated by this Note shall be made in writing and delivered: (a) personally or sent by first class registered or certified mail, overnight courier service or facsimile or electronic transmission to the address designated in writing, (b) by facsimile to the number most recently provided to such party or such other address or fax number as may be designated in writing by such party or (c) by electronic mail, to the electronic mail address most recently provided to such party or such other electronic mail address as may be designated in writing by such party. Any notice or other communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt of written confirmation, if sent by facsimile or electronic transmission, one (1) business day after delivery to an overnight courier service or five (5) days after mailing if sent by mail.

 

10.       Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF DELAWARE, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

 

11.       Severability. Any provision contained in this Note, which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

 

 

 

12.       Trust Waiver. Notwithstanding anything herein to the contrary, the Payee hereby waives any and all right, title, interest or claim of any kind (“Claim”) in or to any distribution of or from the Trust Account in which the proceeds of the initial public offering (“the “IPO”) conducted by the Maker (including the deferred underwriters’ discounts and commissions) and the proceeds of the sale of the units issued in a private placement that occurred prior to the closing of the IPO were deposited, as described in greater detail in the Maker’s Registration Statement on Form S-1 (File No. 333-251037) filed with the Securities and Exchange Commission in connection with the IPO, and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever.

 

13.       Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Maker and the Payee.

 

14.       Assignment. Maker may not assign or transfer this Note or any of its rights or obligations hereunder (by operation of law or otherwise) without the prior written consent of Payee and any attempted assignment without the required consent shall be void.

 

[Remainder of page intentionally left blank. Signature page follows.]

 

 

 

 

 

IN WITNESS WHEREOF, the Maker, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first above written.

 

  MedTech Acquisition Corporation
     
 

 By:

 /s/ Christopher C. Dewey
    Name: Christopher C. Dewey  
    Title: Chief Executive Officer

 

 

 

 

MedTech Acquisition Sponsor LLC

     
 

 By:

 /s/ David J. Matlin
    Name: David J. Matlin
    Title: Managing Member
     

 

 [Signature Page – Promissory Note]

 

 

 

 

 EX-101.SCH 4 mtac-20230612.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 mtac-20230612_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 mtac-20230612_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant [Member] Common Class A [Member] Warrant [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Units, each consisting of one share of Class A Common Stock and one-third of one Redeemable Warrant EX-101.PRE 7 mtac-20230612_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Jun. 12, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 12, 2023
Current Fiscal Year End Date --12-31
Entity File Number 001-39813
Entity Registrant Name MedTech Acquisition Corporation
Entity Central Index Key 0001826667
Entity Tax Identification Number 85-3009869
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 48 Maple Avenue
Entity Address, City or Town Greenwich
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06830
City Area Code 908
Local Phone Number 391-1288
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant
Trading Symbol MTACU
Security Exchange Name NASDAQ
Common Class A [Member]  
Document Information [Line Items]  
Title of 12(b) Security Class A common stock, par value $0.0001 per share
Trading Symbol MTAC
Security Exchange Name NASDAQ
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol MTACW
Security Exchange Name NASDAQ
XML 9 tm2318652d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001826667 2023-06-12 2023-06-12 0001826667 MTAC:UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember 2023-06-12 2023-06-12 0001826667 us-gaap:CommonClassAMember 2023-06-12 2023-06-12 0001826667 us-gaap:WarrantMember 2023-06-12 2023-06-12 iso4217:USD shares iso4217:USD shares 0001826667 false --12-31 8-K 2023-06-12 MedTech Acquisition Corporation DE 001-39813 85-3009869 48 Maple Avenue Greenwich CT 06830 908 391-1288 false false false false Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant MTACU NASDAQ Class A common stock, par value $0.0001 per share MTAC NASDAQ Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share MTACW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $B!SU8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !(@<]6GJS4H>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)VEQ#Z&;B^))07!!\1:2V=U@TX9DI-VW-XV[740?0,@E,W^^ M^0;2F2#-&/$YC@$C.4PWL^^')$W8LB-1D #)'-'K5.?$D)O[,7I-^1H/$+3Y MT >$AO,->"1M-6E8@%58B4QUUD@34=,8SWAK5GSXC'V!60/8H\>!$HA: %/+ MQ'":^PZN@ 5&&'WZ+J!=B:7Z)[9T@)V3FI++N\@X.WI\:6L6[DA MD1X,YE?)23H%W+++Y-?V[G[WP%3#F[;BFTK<[AHN13[B?7']X7<5]J-U>_>/ MC2^"JH-?_T)] 5!+ P04 " !(@<]6F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M $B!SU8%*W;HH@4 (X: 8 >&PO=V]R:W-H965T&UL MO9EO<]I&$,;?]U/H71@+=PT^[M_O M&KJGK_V>&5!>\9N 5?[DF)E;F4OYV9R,P_.68X@@AD ;"8XO]S"".#9*R/%E M(]JJOM,,?'J\57]3WCS>S)SG,)+QG0AU=-[JM5@("U[$^D:NWL'FAHZ-7B#C MO/S/5IMKG18+BES+9#,8"1*1KE_YPR80^PSP-@.\DGO]127E!==\<*;DBBES M-:J9@_)6R]$()U*3E:E6^*G <7HPDO>@SCH:ILA< M[X!YCN?_?7@'"2H,K\+P2CU_A]Z%# K,M6;C=#W33,8^?<"KV%A#DO]9A[B6 M/*J7--/Y-,]X ./:801TI5/+U]>&Y@*7*M.$;LFB>U$:)UKB"<01"Q8?"E M$+DHZW@D52956=,$:;\B[>]#.L*L*LSH. WA@;V'QSI66LG! /:\;K=[0F"Y MCNVDSCY@,_[ QB'2B84(UHUL=X(;)'O';=]Q^KUNGR)\TNO=?0C':6 SM\Q_+OB&5;;\![2@NIZKO4 E^[B7Z..S!D&2_2H#Z0M.9H1J%9NW#I+O\UVD3F&DOY#Y'MGGNTHM/M^0[% M9OW";3",D@P7N+M1:(&^TZ- K$&X='?_((UA32*94@[1(.+W7;2L'DED+<*E M>_N=$EJ#Z>=)4J2;YI;74M%"3>L.UWJ!2[?PJ8Q%@"Z3+K&Z-:X^>%S+0ZLT M\7C6 SRZ84\4M ,,#V!]K9>'N$(#Q3XN%O7Y:]!K)+.]WZ.[\S_(QGE>(%DC M("W;"/AD![!7W[],0"U-/M^B@H[,9,MX6NON#8):D6W>LVW>:VCS9@L)(;N6 MF$_);G-@.@)V^:!-[$(VP_729JFS7@#7PM+?T1A'V_<]ND??ID)C3P6.J[ MZQ/7:3IO=<9FN%/NU9_Z+<&I3JZNB 95RQ>QX7P%XYAV:3R3)TV++X*'[K ME#YM;,W%TR!@BH?(C&.U:^]=.@U!C[?C6_WS:__;Q*%KBN1/0>I3_#3S* M_Q8>Y5N/\E_,HQJ4-@G:VM0JDBB\VF0-'D %(B\-!V/3;%L;%:[1O[:C@65* M!.605ZY[>.SL5X#6O?S_ZEX- J8 [R@4ZU[^2[E7@]#N"NP\>;I@GM1<<;- MSUD,"U1R#D]P8JKUPX_UB999^&UL MW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75E MW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R M5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :# M7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T% M8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE M+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 M Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2S MP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DM MC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D M7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$ MKQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3 M\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ 2('/5I>*NQS $P( L !? M3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2 M?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:>IK&H MP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[ MA$O\G7D(GP&LK\,S4 M-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0& M[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y: MYU;*O8=7LN48Y0]02P,$% @ 2('/5B0>FZ*M ^ $ !H !X M;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D M6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP M#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZT MYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( $B!SU9ED'F2&0$ ,\# 3 M 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP M 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=. M8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9 MP&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I& M0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC", MS[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^DX K @ $0 M@ &O 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " !(@<]6F5R<(Q & M "<)P $P @ ', 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ M 0(4 Q0 ( $B!SU8%*W;HH@4 (X: 8 " @0T( !X M;"]W;W)K&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " !(@<]699!YDAD! #/ P $P @ 'O L$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" Y%0 ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 4 24 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://medtechacquisitioncorp.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2318652d1_8k.htm mtac-20230612.xsd mtac-20230612_def.xml mtac-20230612_lab.xml mtac-20230612_pre.xml tm2318652d1_ex10-1.htm tm2318652d1_ex3-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2318652d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 30 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "mtac-20230612_def.xml" ] }, "inline": { "local": [ "tm2318652d1_8k.htm" ] }, "labelLink": { "local": [ "mtac-20230612_lab.xml" ] }, "presentationLink": { "local": [ "mtac-20230612_pre.xml" ] }, "schema": { "local": [ "mtac-20230612.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 1, "memberStandard": 2, "nsprefix": "MTAC", "nsuri": "http://medtechacquisitioncorp.com/20230612", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2318652d1_8k.htm", "contextRef": "From2023-06-12to2023-06-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://medtechacquisitioncorp.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2318652d1_8k.htm", "contextRef": "From2023-06-12to2023-06-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "MTAC_UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units, each consisting of one share of Class A Common Stock and one-third of one Redeemable Warrant", "label": "Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant [Member]" } } }, "localname": "UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember", "nsuri": "http://medtechacquisitioncorp.com/20230612", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001104659-23-071602-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-071602-xbrl.zip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

$QY<\%.P/ MX8N0>ZPKPT"&'.]@YWSY/='_*8EB=[K2%UW?$03T=:,5*"G]()RQL.>L8W]) MW,@E&G/T(JW52@UXPUYXSI=$OLM]^2*D*W6+<6;G>"3#&??=OX7#N.\P<>," M#OZ,);![B&Q6% .3(\UW-HIY+/"#X;W%' DDST4H)BLXQ1"IJ%9XQ*;2\^0R M>ON_.X%QY_2\S[K]\_/19:<[N/CC]X/C _I\V>GUS.<[;[ITG7B.2X]_/B K MUQY?&2C72*#-/7-L8!@.M"5LCWMFE8;0>A7\U1ZE K=OXS$4Q*>L+.$_)&$X+HX$91,HG$EP0LA[=B7.,*6HGP E4 M;0V="($_LK'IA3M1IJC*(<6:+<*GQ6J B][>8CF+=.=-4N;GA1_^NU)J>40& MX.39M'R5:6D]G6D! P(:($$<'D @2>*B>]Z\:=V>9>[V,K?OI%_>1\2>7J+0 MIM;<.G,2M*>.#.+,GG*PX^$"UET+=BTSNSV7'@1/%"^]_N5G P!V4*(6)MF6F8@@,,(Q8R'*--223>2$^7"XHB]:KRL3>J I,5^ M:S3A+;ZV:ER_"OTZI==7%A'_6^.->E-S[T!<[::.R/)/,G3C50FYY-V2&!CK MXVE"H+E8 !,5Z0 %K\5R)F!=R-!#L @N>8+9'H] 7&NKL@WR$+NXD)V60E8 M1]/11P4E!W+'OP+D-\N=P'R*$I1O/ M"5H0RFL(K?"T,4@H3XBVI4#;PXE\JM#[HWN^R]=F5J\TL?Y^+%FYI@-?=)!D3\>P@W]C/*[S,)ZS=:&Q=2",H> 4B4X3SV.% M'.V1?=W7 J3_57:\A;\IH]H?3SI)/ ?]QT2WRP,W!CT9H>:UCSZ>-*H58K;$ MJWY"D2QJYAR4A#2. ZM(U=5'6P,@U;68X)#]D*YR<(TAN^9>0HKVTW'C^/BX MR0* 1\ LMIR[]KPLB^(I?M4*G)(;10 #KCV=NG)^W!25=]K=DP.,'Z058F<'W;2U"2JQ5T@,WCLAV,ITU@JY*=@E!,11B"I&SCW*594:V4PE'NXYT,60I<7;+P&O=7X'1"5U!P&PHYM4 95FPB\)Q I2/$!18Z0G\" MZI*8^3*&-:#?)'(;HJUAX:M?\("!EZ!; \R#P .;.O&$50YB@Q#-DA)*\%*4 M@/@K2BSRI3GX $Z$U[!Z"@M1 = )UN\0;166PXEM1^@W]I8:S6JIMUZ'99S9QP8MLB MBN!3>KO:)99UE>&#D0&T\Q'(%E80]MO.!;\LDS+D3XF@);XG,)1*]]*XSM,- MP4Z%XDOB(K@@5[J-,1@O"[JKE9U1=RTU/K2775SKB CL?+X$0<97'P)%RAD5 ML'Z-5*V=&GW3?JJM=W$K1] M=?KYR],';3I+>P[=;B.>HYWJ@MKD>=4*N#^(A4B$P(, :X!)^QPL9%CPGS@$ M)W,(KVS"(98J\?$#WXU=RJ9P [+%5VASUGT]JKM$OP1"[*VJE2105AN,@XQR M]=;3!#ZA'05T)JYONB^4#X*YBH%;8/9=-,_RUO?#S>3*@GP%2UDV,FS*W>XV M/8]N=!YQPW2K?QP>LC-7>,Y;=LEGXAW PRJYC8K+#@^-1>B!'I:T?9NTPUKG M]S5>FT"N+L+TVJG'0<::@%8D/=-S#>73!^V;]W%<7)UX_M9]3)<@M3NX_ MSTXNS^*448/%0C@N< #KL--8==[9< IA*YR65:UPBH$YE@<7,O%C8^I]@6_5 M,DP:;"$0CQ@&ZA#09RW1LO9P*&9N%&NT23X4 M=)^=R7"A&# J;PW\RV4$"/EC8Z2#:Q#3!/#&I QZ]_8<^[/!#E# MR#8I[]B( D;][IK#AXMU(RF#$[CI LC/.K(OCP$A;,FJ]%8+^2;@JSQU(T-= MR5Y6MAE%/9CS.R* V"!6_.,L#D&BJ'",HK&YUQB_KU8Z:L'N/5 3)YX;S74> MCL FPA=3-Q6ZRP06V"IZ,!D@]GL=6.2CU&'!H5Y(!%,<9Z$@0JL5R.+LT)UD M,E#.D08>E !-,LC@R3HA7W)*Y%T<&0*<<9. @[CS&SC?&B6L28!7?]*5J[+5 M#IR[]!+9C8*BIG2;84IR#AS2($CM9Q["[J$#I%H*'ONJ. MWP)*'#/]>@Z[."YFAII@W!3-=!D&!1"RD7@B7QL MJ/6D-)JTJ/J6WHVH.&*1AI;HU@R8U'SH.+WD^-W289'$QUH/8JQQ Y3B:"=: M$.:OL@$.UE(C!B^Q:F*978:%D8JTP=%S=14%8]\,D4CE#[HZ!O9*^"1>7#F= MB49"<<(!.:GEBJ'9%(6I6( ^2CNAQEP=SYN";H>K$A&8:/"2](DR@ZP ?#^< M-;Z QTZ$-VQ #]PJ( [P 96=)DV78?-R5!0$G4^ '$/RY2OG7ZWH CA522(A M/JM>G[* BB7%+M;6VE"A(5OC!@W)%M(!MZF:JBB,A?*8\HAXPXA0LZ=#1@@KCNUA>:D\?84.T:, MJI3B<"=J'&NB6(Y5]D$;_&K%]=.^S%KP^*9.#1GV/BMEYM+7?"*O5!+Y$V'7 M)?5.B8\&!)G$>L(5SN0:B6]A2J^>DNX'>6B4'6E J5+7Y?- MX(W W& M^?R\6Q;8J&\WJAE4!D;#1*71$%PD1).QS%65,W%5K8DI6D20HS1F M-(X3,M>9!$+JA&E:A 6QPA0 (Y=HK:VR&5@8_!K&5#U/DMZY]OGFZ7/"5FK' MOZN<\!NL:&&W][)0)C2N(G-?:&!WA7GK7D=%%L8KXOM<)VG#SIG,2@8 ($9S MNR*=YM<4\+@A6[>JV@G"66;%T4VL=WNYVGJ7S5A&^&]%48>2$'XMR5KR&:2= M4:S840:QD*"HAC!$%9^TBT1\/(@K8AU\81\LG;A">9[4]2!5JV;7F>ZCUL@^ M&P;5R(6,$ MF?9CP8U ?*AB$"TND!F"R\0WW"!TJQ#24HW,+'SV)=M@&TJ,YX+O="CT@>P4 M4U%WDJ@#+^LO0K >XBG1I,9ZVS-S_$]87O]Q/=JOWX)'$]^C1WL"CS783'.H M9!EEZ9&:U2A/NCXE?C[KRJB#!WYY& MMGGG2I?F6\"MWFEF.)MBH18>I0QI"J0(R:5!\1P;B*'0+I"F2_,L,I.F5'JB MLHL?N8Y)8G:A_U0S"6;#W5V[UG/7KJ1K]X 6XHE/_P?V7K\]HO?*U1:V^#%6 MF][&D3D"B[7DL["^@H-1H8A7_R<."RLVB1WC\%>,#IVF*\!;%<*^8CQ\1Z>S MVY,8GZ/Z)&GP>IYF*."S5.50W&#_3CA/;;U_8/UM'C]]^/GJ.?:\U8C)1S5) MQ@9ZG#A2Y>5\!:5:*2M&E'41[A-CHDZJ87Y,&E$R\$M\>" ;TU>/$U0K6V>/ M*U MEARJ)9D9]-YI4.VA3L*7;^U M8D]:K\UX\;/*Q)?<.>K>E>:]K)#%A)[9$>I1I,K;)J M8=;KH\=4.37ZK#5S >Q><(?F PKK6S6'UM.SN+=I!:N*PG,K6+>"\:FJIV\# M6[GQ(?TXBG%A:74V]0O;^@R:B^5%]+2_H.HN:D8H?5PEE3/]%&X@PD,Z@&J% M*M\6#@5Q-4E.17.K4#5G?#;#QWSQ,1 UA1?3W)/4FW?S@(2T\E M#AMM#LH"WZ2:['P6!PP?X_GHF,S,3;,5S[-)(3E5[_^9^$(-5CW_;O-3;V5!QS=+<@[D_;'5I__JEY^WI?.E MF!?O;AYON?M>AW5:K(OM1'FM%CTIUJ+O5Z$XBHX4S=UYZ(+S#M#)=QL0&"S% MZM%EY*%C^ LP?KOY^V!;_9#\&V,!X=$8Z(HIZY/[PKJ$&GH-]R1'=_CYS>UI MT-X;;_-PV,MW;$CI0/26G7,(R;Z9KM/^![?NQ+EO+Q_==[)EAW^$OS=+OU9# MOU/[7U!+ 0(4 Q0 ( $B!SU;[!/E ]P, )4. 1 " M 0 !M=&%C+3(P,C,P-C$R+GAS9%!+ 0(4 Q0 ( $B!SU;1;7,\. D M %M 5 " 28$ !M=&%C+3(P,C,P-C$R7V1E9BYX;6Q0 M2P$"% ,4 " !(@<]6%&UL4$L! A0#% @ 2('/5N)Q4!*"" ME6< !4 ( !@QH &UT86,M,C R,S V,3)?<')E+GAM;%!+ M 0(4 Q0 ( $B!SU8!:Y_^5!\ $6Z 2 " 3@C !T M;3(S,3@V-3)D,5\X:RYH=&U02P$"% ,4 " !(@<]6T-*8,$85 !/7 M%@ @ &\0@ =&TR,S$X-C4R9#%?97@Q,"TQ+FAT;5!+ 0(4 M Q0 ( $B!SU8&HF5-7Q *Y6 5 " 398 !T;3(S G,3@V-3)D,5]E>#,M,2YH=&U02P4& < !P#/ 0 R&@ end